Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-12
2011-04-12
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S929000, C514S930000
Reexamination Certificate
active
07923455
ABSTRACT:
The present invention relates to a method for the prevention or the treatment of heart failure comprising administration of a therapeutically effective amount of an anticholinergic 1, medicaments for the prevention or treatment of heart failure comprising one or more, preferably one anticholinergic 1, and methods for the preparation of these medicaments.
REFERENCES:
patent: WO 2005/007142 (2005-01-01), None
Uren et al. (Eur Heart J. (Jun. 1993); 14(6):744-50).
Gross et al. (Chest. (Dec. 2004); 126(6):1946-53).
Cedars-Sinai (“Health Conditions: Congestive Heart Failure”; http://www.csmc.edu/5655.html (2007)).
Fiutowski et al. (Kardiol Pol. Dec. 2004;61(12):561-9; discussion 570).
Rasche, K. et al., “Pulmo Cardials: Effect inhalativer Bronchodilatatoren auf den Atemwegswiderstand bei acuter inksventrikluaerer Funktionsstoerung,” Pneumologie, Berlin, Germany, vol. 44 No. Suppl. 1, Feb. 1990, pp. 533-535, XP000924970.
Kindman, L. Allen et al., “Abnormalities of pulmonary function in patients with congestive heart failure, and reversal with ipratropium bromide,” American Journal of Cardiology, vol. 73 No. 4, 1994, pp. 258-262, XP008073517.
Rolla, G. et al., “Bronchodilating effect of ipratropium bromide in heart failure,” European Respiratory Journal, vol. 6 No. 10, 1993, pp. 1492-1495, XP008073532.
Kindman, L.A. et al., “Pulmonary abnormalities in congestive heart failure reversal by the inhaled anticholinergic agent ipratropium bromide,” Journal of the American College of Cardiology, vol. 19 No. 3 Suppl. A, 1992, p. 161A, XP008073531.
Yesildag, O. et al., “Pulmonary abnormalities in congestive heart failure: reversal by the inhaled anticholinergic agent ipratropium bromide,” European Heart Journal, vol. 21 No. Abstract Suppl., Aug. 2000, ph. 660, XP008073533.
Khan, K.A. et al., “Pulmonary function profle in chronic congestive heart failure and the effect of heart ipratropium bromide,” Indian Heart Journal, 2000, India, vol. 52 No. 3, pp. 297-300, XP008073530.
Kesten Steven
Viel Klaus
Boehringer Ingelheim International GmbH
Krass Frederick
Morris Michael P.
Petka Wendy A.
Simmons Chris E
LandOfFree
Medicaments for the prevention or treatment of heart failure... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicaments for the prevention or treatment of heart failure..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicaments for the prevention or treatment of heart failure... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679452